Belite Bio shares jump on Canaccord Buy initiation for tinlarebant
Canaccord Genuity initiated Belite Bio with a Buy rating and $303 price forecast, citing upside tied to FDA-accepted tinlarebant marketing application. Shares were up 9.63% to $187.56.